Eurofins Bioanalytical Services launches Surrogate Virus Neutralizing antibody detection assays against the SARS-CoV-2 (COVID-19)
Share Article
Eurofins Bioanalytical Services, a member of Eurofins BioPharma Services, Laboratory Testing division, announces the launch of a Surrogate Virus Neutralization Test (sVNT) antibody assay against the SARS-CoV-2-virus. An alternative to conventional testing with a live virus, this assay is the first neutralizing antibody serology test authorized by the FDA as emergency use authorization (EUA). This innovative assay detects the presence of neutralizing/blocking antibodies against SARS-CoV-2 virus, that block the interaction between the receptor-binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor.
Related Keywords
United States , Kristen Galkowski , Eurofins Scientific Group , Eurofins Bioanalytical Services , Eurofins Biopharma Service , Laboratory Testing , Eurofins Biopharma Services , Eurofins Central Laboratory , Euronext Paris Stock Exchange , Bioanalytical Services , Surrogate Virus Neutralization Test , Biopharma Service , Eurofins Scientific , Press Release , ஒன்றுபட்டது மாநிலங்களில் , ஆய்வகம் சோதனை , உயிர் பகுப்பாய்வு சேவைகள் , ப்ரெஸ் வெளியீடு ,
comparemela.com © 2020. All Rights Reserved.